Compare New York Times Co (NYT) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Philip Morris International Inc. — how do they compare? New York Times Co trades at $66.32 (market cap $10.74B), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 29.1× New York Times Co's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Philip Morris International Inc. for 85 Days on average.
| NYT | PM | |
|---|---|---|
Market Cap | $10.74B | $312.50B |
Volume | 2,096,352 | 5,517,172 |
Sector | Media | Consumer Staples |
52-Week High | $85.86 | $200.50 |
52-Week Low | $54.66 | $144.33 |
Typical Hold Time | 81 Days | 85 Days |
Enterprise Value | $10.14B | $355.62B |
Dividend Yield | 1.38% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.32, up 2.19% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. The stock shows a bullish technical signal with key support at $65-66 and resistance at $67-68, while maintaining robust profitability with 51.41% gross margins and 13.19% net income margin. Recent developments include a declared $0.23 dividend and ongoing AI copyright litigation.
Outlook remains positive with analyst consensus target of $84 representing 27% upside potential, though risks include the shareholder lawsuit alleging bias and competitive pressures in digital media. The company's strong cash flow generation and dividend payments provide shareholder value, while earnings growth trajectory supports continued valuation expansion if execution remains solid.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
